个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Paul Martin[1,*1] * ; Ahmed A. Awan[2] ; Marina C. Berenguer[3,4,5] ; Annette Bruchfeld[6,7] ; Fabrizio Fabrizi[8] ; David S. Goldberg[1] ; Jidong Jia[9,10] ; Nassim Kamar[11,12,13] ; Rosmawati Mohamed[14] ; Ma´rio Guimara˜es Pessoˆa[15] ; Stanislas Pol[16] ; Meghan E. Sise[17] ; Ethan M. Balk[18] ; Craig E. Gordon[19] ; Gaelen Adam[18] ; Michael Cheung[20] ; Amy Earley[20] ; Michel Jadoul[21,*2] ;
单位： [1]Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA [2]Selzman Institute forKidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA [3]Department ofGastroenterology, Hepatology Unit & Instituto de Investigación La Fe, Hospital Universitari i Politècnic La Fe, Valencia, Spain [4]Centro deInvestigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain [5]School of Medicine, University ofValencia, Valencia, Spain [6]Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden [7]Department ofRenal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden [8]Division of Nephrology, MaggioreHospital and Foundation IRCCC Cà Granda Ospedale Maggiore Policlinico, Milano, Italy [9]Liver Research Center, Beijing Friendship Hospital,Capital Medical University, Beijing, China [10]Beijing Key Laboratory of Transitional Medicine on Liver Cirrhosis, National Clinical ResearchCenter for Digestive Diseases, Beijing, China [11]Departments of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France [12]INFINITY- Inserm U1291-CNRS U5051, Toulouse, France [13]Université Paul Sabatier, Toulouse, France [14]Department of Medicine, UniversityMalaya Medical Centre, Kuala Lumpur, Malaysia [15]Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology,University of São Paulo School of Medicine, São Paulo, Brazil [16]Hepatology Department, Hopital Cochin, Université Paris Descartes, Paris,France [17]Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA [18]Center forEvidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA [19]Tufts Medical Center, Division ofNephrology, Boston, Massachusetts, USA [20]Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium [21]Department ofNephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
出处：
DOI： 10.1016/j.kint.2022.07.012
ISSN：

摘要：
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 泌尿学与肾脏学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 泌尿学与肾脏学
JCR分区：
出版当年[2020]版：
Q1 UROLOGY & NEPHROLOGY
最新[2023]版：
Q1 UROLOGY & NEPHROLOGY

影响因子： 最新[2023版] 最新五年平均[2021-2025] 出版当年[2020版] 出版当年五年平均[2016-2020] 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA [*1]Division of Digestive Health and Liver Diseases, Miller School of Medicine, University of Miami, Miami, Florida 33136 USA
通讯作者：
通讯机构： [1]Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA [21]Department ofNephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium [*1]Division of Digestive Health and Liver Diseases, Miller School of Medicine, University of Miami, Miami, Florida 33136 USA [*2]Cliniques universitaires Saint-Luc, Nephrology, Université catholique de Louvain, Avenue Hippocrate 10, Brussels 1200, Belgium
推荐引用方式(GB/T 7714)：
Paul Martin,Ahmed A. Awan,Marina C. Berenguer,et al.Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease[J].Kidney International.2022,102(6):1228-1237.doi:10.1016/j.kint.2022.07.012.
APA：
Paul Martin,Ahmed A. Awan,Marina C. Berenguer,Annette Bruchfeld,Fabrizio Fabrizi...&Michel Jadoul.(2022).Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.Kidney International,102,(6)
MLA：
Paul Martin,et al."Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease".Kidney International 102..6(2022):1228-1237

资源点击量：1320 今日访问量：0 总访问量：816 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）